Brad Kahl, MD

Brad Kahl, MD, is professor of medicine in the Division of Oncology at the Washington University School of Medicine and director of the Lymphoma Program at the Alvin J. Siteman Cancer Center in Saint Louis, MO. 

He received his medical degree from Tufts University, where he was elected to the Alpha Omega Alpha Medical Honor Society. He then received training in internal medicine and in hematology at the University of Wisconsin. He served on the faculty at the University of Wisconsin prior to joining the faculty at Washington University in 2015. 

Dr Kahl’s clinical interests involve the care of patients with Hodgkin lymphoma, non-Hodgkin lymphoma, and chronic lymphocytic leukemia. His research focuses on the development of novel treatments for patients with lymphoma, with an emphasis on novel targeted agents. He has been the principal investigator for multiple clinical trials.  

Dr Kahl is a member of several professional organizations, including the American Society of Hematology, the American Society of Clinical Oncology, and the Eastern Cooperative Oncology Group. He is the chairman of the Eastern Cooperative Oncology Group Lymphoma Committee and a member of the Lymphoma Research Foundation Scientific Advisory Board.